{"a":[{"_":"New MFN deal details reignite concerns that Trump's pricing policy favors pharma","$":{"href":"/pharma/new-mfn-deal-details-reignite-concerns-trumps-pricing-policy-favors-pharma","hreflang":"en"}}]}

Summary

Newly revealed details about the Trump administration's most favored nation drug pricing deals have reignited concerns from lawmakers and advocacy groups that the policy may disproportionately benefit pharmaceutical companies. The redacted information has prompted further scrutiny of the pricing arrangement's implications.